These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 961464)

  • 1. L-alpha-hydroxycholecalciferol treatment of adults with chronic renal failure.
    Madsen S; Olgaard K
    Acta Med Scand; 1976; 200(1-2):1-5. PubMed ID: 961464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease.
    Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; de Luca HF
    Proc Eur Dial Transplant Assoc; 1976; 12():227-36. PubMed ID: 935115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study.
    Berl T; Berns AS; Hufer WE; Hammill K; Alfrey AC; Arnaud CD; Schrier RW
    Ann Intern Med; 1978 Jun; 88(6):774-80. PubMed ID: 208439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1-alphahydroxycholecalciferol in chronic renal failure. Studies of the effect or oral doses.
    Davie MW; Chalmers TM; Hunter JO; Pelc B; Kodicek E
    Ann Intern Med; 1976 Mar; 84(3):281-5. PubMed ID: 1259263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term therapy of uremic osteodystrophy in adults with calcitriol.
    Moorthy AV; Harrington AR; Mazess RB; Simpson DP
    Clin Nephrol; 1981 Aug; 16(2):93-100. PubMed ID: 6894893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization.
    Fournier A; Bordier P; Gueris J; Sebert JL; Marie P; Ferrière C; Bedrossian J; DeLuca HF
    Kidney Int; 1979 Feb; 15(2):196-204. PubMed ID: 513484
    [No Abstract]   [Full Text] [Related]  

  • 8. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1-alpha-hydroxycholecalciferol for renal osteodystrophy.
    Brownjohn AM; Goodwin FJ; Hately W; Marsh FP; O'Riordan JL; Papapoulos SE
    Br Med J; 1977 Sep; 2(6089):721-3. PubMed ID: 912269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.
    Junor BJ; Catto GR; Macleod M
    Calcif Tissue Res; 1977 May; 22 Suppl():112-6. PubMed ID: 912512
    [No Abstract]   [Full Text] [Related]  

  • 11. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
    Massry SG; Goldstein DA; Malluche HH
    Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
    Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Renal osteodystrophy: the importance of 1-alpha-OH-D3].
    Berland Y; Olmer M; Grandvuillemin M; Lachaize AM
    Sem Hop; 1981 Mar 8-15; 57(9-10):445-9. PubMed ID: 6261385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1alpha-hydroxycholecalciferol: a promising therapeutic approach for renal osteodystrophy.
    Gotloib L; Mines M; Mazur Y; Sklan D; Garmizo AL; Jancu J; Israeli M; Malul M
    Isr J Med Sci; 1978 Jul; 14(7):731-5. PubMed ID: 681163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function.
    Nielsen HE; Rømer FK; Melsen F; Christensen MS; Hansen HE
    Clin Nephrol; 1980 Mar; 13(3):103-8. PubMed ID: 7379358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of 1alpha-hydroxyvitamin D3 on calcium and mineral content of bone in renal osteodystrophy.
    Junor BJ; Catto GR
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():131s-138s. PubMed ID: 606411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term experience of alfacalcidol in renal osteodystrophy.
    Sharman VL; Brownjohn AM; Goodwin FJ; Hately W; Manning RM; O'Riordan JH; Papapoulos SE; Marsh FP
    Q J Med; 1982; 51(203):271-8. PubMed ID: 7146311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled trial of 1apha-hydroxycholecalciferol in chronic renal failure.
    Tougaard L; Sorensen E; Brochner-Mortensen J; Christensen MS; Rodbro P; Sorensen AW
    Lancet; 1976 May; 1(7968):1044-7. PubMed ID: 57451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1-alpha-hydroxyvitamin D3 in chronic renal failure. A potent analogue of the kidney hormone, 1,25-dihydroxycholecalciferol.
    Chan JC; Oldham SB; Holick MF; DeLuca HF
    JAMA; 1975 Oct; 234(1):47-52. PubMed ID: 1174223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.